Tranexamic Acid (TXA) Dosing in Primary Total Knee Arthroplasty - Wesley Research Institute
Wesley Research Institute
Donate
Now

The purpose of the study is to evaluate a product called Tranexamic Acid (TXA) and its best use in patients who are undergoing total knee replacement.

Research Objectives

Status

Current

Recruitment

Open

Estimated completion

December 2023

Patient Group

Patients undergoing total knee replacement surgery (arthroplasty)

Total Participants

80

Study location

Wesley Research Institute, Griffith University

Study type

Investigator Initiated
find out if you’re eligible

Lead investigator

  • A/Prof Susan Clark

Experienced investigator

  • Prof Robert Ware

Clinical trial coordinator

  • Emma Craig

Technical title

A Prospective, Randomised Non-Blinded Pilot Study to Optimise Oral Tranexamic Acid Dosing in Primary Total Knee Arthroplasty (TXA002)

About this research project

The purpose of the study is to evaluate a product called Tranexamic Acid (TXA) and its best use in patients who are undergoing total knee replacement. The product is currently used to reduce bleeding during and after surgical procedures. This can lessen the chance of you needing a blood transfusion and may decrease pain, swelling and recovery time following the operation. Tranexamic Acid is already routinely used by surgeons for patients having joint replacements but there is currently no accurate information about the best dosing of the drug to achieve optimal patient outcomes. This study will assess whether different treatment durations will lead to better results for patients.

Latest News

Queensland Scientists Win Prestigious NHMRC Science to Art Award

A breathtaking image capturing the intricate details of skin cancer has earned the Queensland Spatial Biology Centre (QSBC) scientists the prestigious 2025 National Health and Medical Research Council (NHMRC) Science to Art Award.

Advancing Coeliac Disease Research

For decades, the gluten-free diet has been the only option for the 1 in 70 Queenslanders – over 80,000 people – living with coeliac disease. Now, clinical trials, spearheaded by Dr James Daveson, Director of the Wesley Coeliac Disease and Immune Health Research Program and the Coral Sea Institute in Mackay, are rewriting the script. 

High Quality Healthcare, No Matter Your Postcode   

A groundbreaking study by Queensland’s Wesley Research Institute, published in Nature’s new journal npj Health Systems, reveals that entrenched biases and systemic barriers are perpetuating these inequities, calling for an urgent reimagining of healthcare delivery across Australia.  
1 2 3 21
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram